病因不明的缺血性中风:个案分析,呼吁多专业预测,预防和个性化的方法。

IF 6.5 2区 医学 Q1 Medicine Epma Journal Pub Date : 2022-12-01 DOI:10.1007/s13167-022-00307-z
Olga Golubnitschaja, Pavel Potuznik, Jiri Polivka, Martin Pesta, Olga Kaverina, Claus C Pieper, Martina Kropp, Gabriele Thumann, Carl Erb, Alexander Karabatsiakis, Ivana Stetkarova, Jiri Polivka, Vincenzo Costigliola
{"title":"病因不明的缺血性中风:个案分析,呼吁多专业预测,预防和个性化的方法。","authors":"Olga Golubnitschaja,&nbsp;Pavel Potuznik,&nbsp;Jiri Polivka,&nbsp;Martin Pesta,&nbsp;Olga Kaverina,&nbsp;Claus C Pieper,&nbsp;Martina Kropp,&nbsp;Gabriele Thumann,&nbsp;Carl Erb,&nbsp;Alexander Karabatsiakis,&nbsp;Ivana Stetkarova,&nbsp;Jiri Polivka,&nbsp;Vincenzo Costigliola","doi":"10.1007/s13167-022-00307-z","DOIUrl":null,"url":null,"abstract":"<p><p>Due to the reactive medical approach applied to disease management, stroke has reached an epidemic scale worldwide. In 2019, the global stroke prevalence was 101.5 million people, wherefrom 77.2 million (about 76%) suffered from ischemic stroke; 20.7 and 8.4 million suffered from intracerebral and subarachnoid haemorrhage, respectively. Globally in the year 2019 - 3.3, 2.9 and 0.4 million individuals died of ischemic stroke, intracerebral and subarachnoid haemorrhage, respectively. During the last three decades, the absolute number of cases increased substantially. The current prevalence of stroke is 110 million patients worldwide with more than 60% below the age of 70 years. Prognoses by the World Stroke Organisation are pessimistic: globally, it is predicted that 1 in 4 adults over the age of 25 will suffer stroke in their lifetime. Although age is the best known contributing factor, over 16% of all strokes occur in teenagers and young adults aged 15-49 years and the incidence trend in this population is increasing. The corresponding socio-economic burden of stroke, which is the leading cause of disability, is enormous. Global costs of stroke are estimated at 721 billion US dollars, which is 0.66% of the global GDP. Clinically manifested strokes are only the \"tip of the iceberg\": it is estimated that the total number of stroke patients is about 14 times greater than the currently applied reactive medical approach is capable to identify and manage. Specifically, lacunar stroke (LS), which is characteristic for silent brain infarction, represents up to 30% of all ischemic strokes. Silent LS, which is diagnosed mainly by routine health check-up and autopsy in individuals without stroke history, has a reported prevalence of silent brain infarction up to 55% in the investigated populations. To this end, silent brain infarction is an independent predictor of ischemic stroke. Further<b>,</b> small vessel disease and silent lacunar brain infarction are considered strong contributors to cognitive impairments, dementia, depression and suicide, amongst others in the general population. In sub-populations such as diabetes mellitus type 2, proliferative diabetic retinopathy is an independent predictor of ischemic stroke. According to various statistical sources, cryptogenic strokes account for 15 to 40% of the entire stroke incidence. The question to consider here is, whether a cryptogenic stroke is fully referable to unidentifiable aetiology or rather to underestimated risks. Considering the latter, translational research might be of great clinical utility to realise innovative predictive and preventive approaches, potentially benefiting high risk individuals and society at large. In this position paper, the consortium has combined multi-professional expertise to provide clear statements towards the paradigm change from reactive to predictive, preventive and personalised medicine in stroke management, the crucial elements of which are:Consolidation of multi-disciplinary expertise including family medicine, predictive and in-depth diagnostics followed by the targeted primary and secondary (e.g. treated cancer) prevention of silent brain infarctionApplication of the health risk assessment focused on sub-optimal health conditions to effectively prevent health-to-disease transitionApplication of AI in medicine, machine learning and treatment algorithms tailored to robust biomarker patternsApplication of innovative screening programmes which adequately consider the needs of young populations.</p>","PeriodicalId":54292,"journal":{"name":"Epma Journal","volume":null,"pages":null},"PeriodicalIF":6.5000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9670046/pdf/","citationCount":"10","resultStr":"{\"title\":\"Ischemic stroke of unclear aetiology: a case-by-case analysis and call for a multi-professional predictive, preventive and personalised approach.\",\"authors\":\"Olga Golubnitschaja,&nbsp;Pavel Potuznik,&nbsp;Jiri Polivka,&nbsp;Martin Pesta,&nbsp;Olga Kaverina,&nbsp;Claus C Pieper,&nbsp;Martina Kropp,&nbsp;Gabriele Thumann,&nbsp;Carl Erb,&nbsp;Alexander Karabatsiakis,&nbsp;Ivana Stetkarova,&nbsp;Jiri Polivka,&nbsp;Vincenzo Costigliola\",\"doi\":\"10.1007/s13167-022-00307-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Due to the reactive medical approach applied to disease management, stroke has reached an epidemic scale worldwide. In 2019, the global stroke prevalence was 101.5 million people, wherefrom 77.2 million (about 76%) suffered from ischemic stroke; 20.7 and 8.4 million suffered from intracerebral and subarachnoid haemorrhage, respectively. Globally in the year 2019 - 3.3, 2.9 and 0.4 million individuals died of ischemic stroke, intracerebral and subarachnoid haemorrhage, respectively. During the last three decades, the absolute number of cases increased substantially. The current prevalence of stroke is 110 million patients worldwide with more than 60% below the age of 70 years. Prognoses by the World Stroke Organisation are pessimistic: globally, it is predicted that 1 in 4 adults over the age of 25 will suffer stroke in their lifetime. Although age is the best known contributing factor, over 16% of all strokes occur in teenagers and young adults aged 15-49 years and the incidence trend in this population is increasing. The corresponding socio-economic burden of stroke, which is the leading cause of disability, is enormous. Global costs of stroke are estimated at 721 billion US dollars, which is 0.66% of the global GDP. Clinically manifested strokes are only the \\\"tip of the iceberg\\\": it is estimated that the total number of stroke patients is about 14 times greater than the currently applied reactive medical approach is capable to identify and manage. Specifically, lacunar stroke (LS), which is characteristic for silent brain infarction, represents up to 30% of all ischemic strokes. Silent LS, which is diagnosed mainly by routine health check-up and autopsy in individuals without stroke history, has a reported prevalence of silent brain infarction up to 55% in the investigated populations. To this end, silent brain infarction is an independent predictor of ischemic stroke. Further<b>,</b> small vessel disease and silent lacunar brain infarction are considered strong contributors to cognitive impairments, dementia, depression and suicide, amongst others in the general population. In sub-populations such as diabetes mellitus type 2, proliferative diabetic retinopathy is an independent predictor of ischemic stroke. According to various statistical sources, cryptogenic strokes account for 15 to 40% of the entire stroke incidence. The question to consider here is, whether a cryptogenic stroke is fully referable to unidentifiable aetiology or rather to underestimated risks. Considering the latter, translational research might be of great clinical utility to realise innovative predictive and preventive approaches, potentially benefiting high risk individuals and society at large. In this position paper, the consortium has combined multi-professional expertise to provide clear statements towards the paradigm change from reactive to predictive, preventive and personalised medicine in stroke management, the crucial elements of which are:Consolidation of multi-disciplinary expertise including family medicine, predictive and in-depth diagnostics followed by the targeted primary and secondary (e.g. treated cancer) prevention of silent brain infarctionApplication of the health risk assessment focused on sub-optimal health conditions to effectively prevent health-to-disease transitionApplication of AI in medicine, machine learning and treatment algorithms tailored to robust biomarker patternsApplication of innovative screening programmes which adequately consider the needs of young populations.</p>\",\"PeriodicalId\":54292,\"journal\":{\"name\":\"Epma Journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.5000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9670046/pdf/\",\"citationCount\":\"10\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Epma Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s13167-022-00307-z\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epma Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13167-022-00307-z","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 10

摘要

由于反应性医疗方法应用于疾病管理,中风在世界范围内已达到流行病规模。2019年,全球卒中患病率为1.015亿人,其中7720万人(约76%)患有缺血性卒中;脑内出血和蛛网膜下腔出血分别为2070万和840万。2019年,全球分别有330万人、290万人和40万人死于缺血性中风、脑内出血和蛛网膜下腔出血。在过去三十年中,病例的绝对数量大幅增加。目前全球卒中患病率为1.1亿,其中60%以上的患者年龄在70岁以下。世界中风组织的预测是悲观的:在全球范围内,预计四分之一的25岁以上的成年人将在他们的一生中遭受中风。虽然年龄是最著名的影响因素,但超过16%的中风发生在15-49岁的青少年和年轻人中,而且这一人群的发病率呈上升趋势。中风是导致残疾的主要原因,其相应的社会经济负担是巨大的。全球中风费用估计为7210亿美元,占全球GDP的0.66%。临床表现的中风只是“冰山一角”:据估计,中风患者总数约为目前应用的反应性医疗方法能够识别和管理的14倍。具体来说,腔隙性卒中(LS)是无症状性脑梗死的特征,占所有缺血性卒中的30%。无声性LS主要通过常规健康检查和无卒中史的个体尸检诊断,据报道,在调查人群中,无声性脑梗死的患病率高达55%。为此,无症状性脑梗死是缺血性脑卒中的独立预测因子。此外,在普通人群中,小血管疾病和无症状腔隙性脑梗死被认为是导致认知障碍、痴呆、抑郁和自杀等的重要因素。在亚人群中,如2型糖尿病,增殖性糖尿病视网膜病变是缺血性卒中的独立预测因子。根据各种统计资料,隐源性中风占整个中风发病率的15%至40%。这里要考虑的问题是,隐源性中风是否完全与无法识别的病因有关,还是与被低估的风险有关。考虑到后者,转化研究可能具有很大的临床效用,以实现创新的预测和预防方法,潜在地使高风险个体和整个社会受益。在这份立场文件中,该联盟结合了多专业的专业知识,为卒中管理中从反应性到预测性、预防性和个性化医学的范式转变提供了明确的声明,其中的关键要素是:整合包括家庭医学在内的多学科专业知识;预测和深入诊断,随后是有针对性的原发性和继发性(例如治疗癌症)预防无症状脑梗死;应用健康风险评估,重点关注次优健康状况,以有效预防健康向疾病的过渡;在医学中应用人工智能,机器学习和针对强大生物标志物模式量身定制的治疗算法;应用充分考虑年轻人群需求的创新筛查方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Ischemic stroke of unclear aetiology: a case-by-case analysis and call for a multi-professional predictive, preventive and personalised approach.

Due to the reactive medical approach applied to disease management, stroke has reached an epidemic scale worldwide. In 2019, the global stroke prevalence was 101.5 million people, wherefrom 77.2 million (about 76%) suffered from ischemic stroke; 20.7 and 8.4 million suffered from intracerebral and subarachnoid haemorrhage, respectively. Globally in the year 2019 - 3.3, 2.9 and 0.4 million individuals died of ischemic stroke, intracerebral and subarachnoid haemorrhage, respectively. During the last three decades, the absolute number of cases increased substantially. The current prevalence of stroke is 110 million patients worldwide with more than 60% below the age of 70 years. Prognoses by the World Stroke Organisation are pessimistic: globally, it is predicted that 1 in 4 adults over the age of 25 will suffer stroke in their lifetime. Although age is the best known contributing factor, over 16% of all strokes occur in teenagers and young adults aged 15-49 years and the incidence trend in this population is increasing. The corresponding socio-economic burden of stroke, which is the leading cause of disability, is enormous. Global costs of stroke are estimated at 721 billion US dollars, which is 0.66% of the global GDP. Clinically manifested strokes are only the "tip of the iceberg": it is estimated that the total number of stroke patients is about 14 times greater than the currently applied reactive medical approach is capable to identify and manage. Specifically, lacunar stroke (LS), which is characteristic for silent brain infarction, represents up to 30% of all ischemic strokes. Silent LS, which is diagnosed mainly by routine health check-up and autopsy in individuals without stroke history, has a reported prevalence of silent brain infarction up to 55% in the investigated populations. To this end, silent brain infarction is an independent predictor of ischemic stroke. Further, small vessel disease and silent lacunar brain infarction are considered strong contributors to cognitive impairments, dementia, depression and suicide, amongst others in the general population. In sub-populations such as diabetes mellitus type 2, proliferative diabetic retinopathy is an independent predictor of ischemic stroke. According to various statistical sources, cryptogenic strokes account for 15 to 40% of the entire stroke incidence. The question to consider here is, whether a cryptogenic stroke is fully referable to unidentifiable aetiology or rather to underestimated risks. Considering the latter, translational research might be of great clinical utility to realise innovative predictive and preventive approaches, potentially benefiting high risk individuals and society at large. In this position paper, the consortium has combined multi-professional expertise to provide clear statements towards the paradigm change from reactive to predictive, preventive and personalised medicine in stroke management, the crucial elements of which are:Consolidation of multi-disciplinary expertise including family medicine, predictive and in-depth diagnostics followed by the targeted primary and secondary (e.g. treated cancer) prevention of silent brain infarctionApplication of the health risk assessment focused on sub-optimal health conditions to effectively prevent health-to-disease transitionApplication of AI in medicine, machine learning and treatment algorithms tailored to robust biomarker patternsApplication of innovative screening programmes which adequately consider the needs of young populations.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Epma Journal
Epma Journal Medicine-Biochemistry (medical)
CiteScore
11.30
自引率
23.10%
发文量
0
期刊介绍: PMA Journal is a journal of predictive, preventive and personalized medicine (PPPM). The journal provides expert viewpoints and research on medical innovations and advanced healthcare using predictive diagnostics, targeted preventive measures and personalized patient treatments. The journal is indexed by PubMed, Embase and Scopus.
期刊最新文献
Resveratrol: potential application in safeguarding testicular health Application of ChatGPT-4 to oculomics: a cost-effective osteoporosis risk assessment to enhance management as a proof-of-principles model in 3PM Association of the weight-adjusted waist index with hypertension in the context of predictive, preventive, and personalized medicine The caregiving role influences Suboptimal Health Status and psychological symptoms in unpaid carers Liver function maximum capacity test during normothermic regional perfusion predicts graft function after transplantation
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1